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Introduction: The use of prokinetic agents on post-pyloric placement of spiral nasojejunal tubes is controversial.
The aim of the present study was to examine if metoclopramide or domperidone can increase the success rate of
post-pyloric placement of spiral nasojejunal tubes.
Methods: A multicenter, open-label, randomized, controlled trial was conducted in seven hospitals in China between
April 2012 and February 2014. Patients admitted to the intensive care unit and requiring enteral nutrition for more than
three days were randomly assigned to the metoclopramide, domperidone or control groups (1:1:1 ratio). The primary
outcome was defined as the success rate of post-pyloric placement of spiral nasojejunal tubes, assessed 24 hours
after initial placement. Secondary outcomes included success rate of post-D1, post-D2, post-D3 and proximal jejunum
placement and tube migration distance. Safety of the study drugs and the tubes during the entire study period were
recorded.
Results: In total, 307 patients were allocated to the metoclopramide (n = 103), domperidone (n = 100) or control group
(n = 104). The success rate of post-pyloric placement after 24 hours in the metoclopramide, domperidone and control
groups was 55.0%, 51.5% and 27.3%, respectively (P = 0.0001). Logistic regression analysis identified the use of prokinetic
agents, Acute Physiology and Chronic Health Evaluation (APACHE) II score <20, Sequential Organ Failure Assessment
(SOFA) score <12 and without vasopressor as independent factors influencing the success rate of post-pyloric placement.
No serious drug-related adverse reaction was observed.
Conclusions: Prokinetic agents, such as metoclopramide or domperidone, are effective at improving the success rate of
post-pyloric placement of spiral nasojejunal tubes in critically ill patients.
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Nutritional support is an important part of the treatment
of critical illnesses, and enteral nutrition is recommended
prior in critically ill patients [1]. Studies have shown that
post-pyloric feeding may reduce gastric retention, regurgita-
tion and aspiration, resulting in decreased incidence of
complications such as aspiration pneumonia [2-4].
Moreover, post-pyloric feeding can improve the efficiency
of enteral nutrition and reduce the time of nutritional
support [5,6]. Guidelines therefore recommend post-
pyloric feeding as the preferred nutritional support route
in critically ill patients with intolerance to gastric feeding.
However, it is not easy to implement post-pyloric feeding
conventionally [7,8].
Despite a number of different methods to place feeding
tubes, no universal standard method is available [9].
Currently, fluoroscopic and endoscopic methods are
mainly used in feeding tube placement [10,11]. Fluoroscopic
and endoscopic methods are reliable but costly, often
requiring transfer of patients and delaying early initiation
of post-pyloric feeding in patients with critical illness [12].
Moreover, radiation exposure is not negligible when
fluoroscopic guidance is used [13]. By-the-bedside
nasojejunal tube placement is possible in more than
80% of patients [14]. No specialized equipment is required,
and patient transport and delay in nutrition may be
avoided [15]. Various bedside techniques, including
air insufflation, pH assisted and spontaneous passage
with or without motility agents, are available to facilitate
transpyloric feeding tube passage [16].
Recently, clinicians have attempted to use a spiral
nasojejunal tube to implement post-pyloric feeding in
critical illness [17]. Spiral nasojejunal tubes consist of a
polyurethane tube, 145 cm long, with a spiraled extrem-
ity and are designed to facilitate spontaneous migration
into the jejunum with the assistance of gastrointestinal
motility after successful gastric placement. Research has
shown that spiral nasojejunal tubes are preferable to
straight tubes for bedside unguided post-pyloric feed-
ing in patients with impaired or normal gastric
emptying [18]. However, the overall success rate of post-
pyloric placement is significantly lower than placement by
endoscopy [19].
Given that self-advancing tubes depend on gastrointes-
tinal motility, researchers have attempted to use prokinetic
agents to improve the success rate of post-pyloric
placement of spiral nasojejunal tubes. Metoclopramide is a
dopaminergic blocker with antiemetic and gastroprokinetic
effects. It is commonly used to treat nausea and vomiting, to
facilitate gastric emptying and to treat migraine-associated
gastric stasis [20]. Domperidone is a specific blocker
of peripheral dopamine receptors. It is used to relieve
nausea and vomiting, to increase food transit through
the stomach by increasing gastrointestinal peristalsis and toincrease lactation [21,22]. However, the results of research
into the use of prokinetic agents are controversial. An early
prospective randomized trial showed no significant rela-
tionship between administration of metoclopramide and
successful tube placement [23]. On the other hand, Lai and
colleagues achieved a success rate of 57% using a spiral tube
compared with 0% using a straight tube in patients with
abnormal gastric emptying who received prior administra-
tion of 10 mg metoclopramide [18]. However, the results of
these studies should be viewed with caution due to their
small sample sizes, differences in baseline data of the study
population and inconsistent dosage of prokinetic drugs. In
addition, the use of domperidone to facilitate nasojejunal
tube placement has not yet been reported.
The aim of the present multicenter randomized con-
trolled trial was therefore to determine the efficacy of
metoclopramide or domperidone in promoting post-pyloric
placement of spiral nasojejunal tubes in critically ill patients.Methods
Study design
A prospective, multicenter, open-label, randomized,
controlled clinical trial was conducted in the ICUs of
seven university hospitals. The study received approvals
from ethic committees of Guangdong General Hospital
(study organizer, approval number GDREC2011132H) and
other participating centers (listed in Acknowledgements).
Written informed consent was obtained from each patient
or from the next of kin for patients unable to consent.
The trial was registered with the Chinese Clinical Trial
Registry (ChiCTR-TRC-12001956) [24].Patients
Consecutive patients admitted to ICUs between April
2012 and February 2014 and requiring enteral nutrition
for more than 3 days were enrolled in the present trial.
Eligibility criteria were: patients admitted to the ICU;
age ≥18 years; and requiring enteral nutrition for more
than 3 days. Exclusion criteria were: history of percutaneous
gastrostomy or gastrojejunostomy; intubation intolerance;
esophageal varices or strictures; previous major gastro-
esophageal surgery (for example, esophagectomy or gastrec-
tomy); pregnant; or history of allergy to metoclopramide,
domperidone, or meglumine diatrizoate.
Patients who fulfilled all eligibility criteria were eligible for
randomization. Computer-generated block randomization
(block size = 6) according to the sequence of recruitment
was used to randomize patients. Clinicians who enrolled
and treated the subjects were not involved in data
collection. Eligible patients were randomly assigned in
a 1:1:1 ratio at each hospital to receive metoclopramide,
domperidone or nothing after telephone verification with
the randomization center.
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A self-propelled feeding tube, 145 cm long, made of
radiopaque polyurethane (CH10; Flocare Bengmark,
Nutricia, the Netherlands) was used in this trial. According
to the method described by Berger and colleagues [17], the
feeding tube was inserted in the supine position, with the
head tilted at 30°. The tube was straightened using the
stylet, and the stylet and tube lumen were lubricated with
10 ml paraffin. The tube was then inserted 50 to 55 cm
down into the larger nostril. The position was confirmed by
air injection to the stomach. The stylet was then pulled out
by about 25 cm with gentle tugs until loose, and the tube
was inserted down 75 to 80 cm. Before removing the stylet,
the position of the tube was again confirmed. The stylet
was removed while maintaining the tube at the nose level
with the other hand and pulling it out. The tube was fixed
on the patient’s face with a free loop of about 40 cm to
allow migration, and the tube was confirmed by abdominal
X-ray scan after 24 hours, before feeding.
According to the trial protocol, patients allocated to
the metoclopramide group received 20 mg (or 10 mg in
cases of renal insufficiency) metoclopramide intravenously
10 minutes before tube insertion. In the domperidone
group, domperidone (20 mg tube feeding × 4/day) was
administered by the tube immediately after it was
successfully placed into the stomach. No drug was
used before and after tube insertion in the control
group. The treating physicians dictated the patients’
care according to their condition, including the venti-
lation regimen, blood glucose control, resuscitation
and hemodynamic support, organ support, sedation or
analgesia as needed and adequate nutrition.
Endpoints
The primary efficacy endpoint was defined as the success
rate of post-pyloric placement (post-pyloric means reaching
the first portion of the duodenum or beyond) of the spiral
nasojejunal tube assessed 24 hours after insertion.
Secondary outcomes included the success rate of
post-D1 (defined as reaching the second portion of the
duodenum or beyond), post-D2 (defined as reaching
the third portion of the duodenum or beyond), post-D3
(defined as reaching the fourth portion of the duodenum
or beyond) and proximal jejunum placement and tube
migration distance (defined as the nose scale of the
tube recorded 24 hours after tube placement minus the
initial nose scale immediately recorded after successful
gastric placement).
The position of the tube was confirmed with air insuffla-
tion, and on abdominal X-ray scan 24 hours after tube
insertion. To help confirm the tube position, additional
hydrosoluble contrast injection of meglumine diatrizoate
was administered via the tube before radiography, if
necessary. Confirmation of tube placement using X-rayexamination was routinely performed after placement, but
there were no additional X-ray examinations. The
placement results were examined by an expert group
of ICU clinicians and radiologists who were independent
and blinded to the allocation sequence. Progression was
considered successful when the tube had at least reached
the duodenum, and according to the part of duodenum it
had at least reached. The exact location of the tube was
confirmed, including stomach, first (D1), second (D2),
third (D3) and fourth (D4) portions of the duodenum, and
proximal jejunum.
Safety
Adverse events of the study drugs and the tubes were
recorded in all patients within 24 hours after tube inser-
tion. Safety assessment was based on the comparison of
all available information obtained from the three groups
with respect to detected outliers in laboratory safety data,
drug-related adverse events (assessed and recorded by the
investigator) and tube insertion-related adverse events
(assessed and recorded by the investigator).
Data collection
Once patients were enrolled, data including demographic
characteristics, diagnosis and concomitant medication
were collected. The following clinical parameters were
recorded after enrollment: severity of illness as assessed
by the Acute Physiology and Chronic Health Evaluation II
(APACHE II) and organ function as assessed by the
Sequential Organ Failure Assessment (SOFA).
Statistical analysis
Based on previous studies [25,26], a sample size of 279
patients was required to show an increase in the 24-hour
success rate from 50% [26] to 70% [25] using prokinetic
agent administration, with a two-sided test (α error = 5%;
power = 80%). Considering a possible dropout rate of 10%,
the trial enrolled 307 patients. All analyses were performed
on the per protocol set basis. Demographic data, outcome
data and other laboratory parameters are presented as
the frequency for categorical variables, and as the
mean ± standard deviation or median with interquartile
range for continuous variables. Proportions were com-
pared with the chi-square test or Fisher’s exact test, as
appropriate. Continuous variables were tested using ana-
lysis of variance and Bonferonni post hoc test for normally
distributed data, or the Wilcoxon rank-sum test for non-
normally distributed data. Patients were stratified on a
number of baseline covariates such as mechanical ventila-
tion, APACHE II and SOFA scores, use of sedative and
analgesic, sex and age. The success rate of post-pyloric
placement was compared between different groups with
adjustment for baseline covariates. Logistic multivariate
stepwise regression (forward) was used to determine the
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with SPSS 13.0 (SPSS Inc., Chicago, IL, USA). Two-sided
P <0.05 was considered statistically significant. P <0.016
was considered statistically significant when any two of
three groups were compared.
Results
Enrollment
Between April 2012 and February 2014, 307 eligible
patients were randomized (Figure 1). In the metoclopramide
group, consent was withdrawn after enrollment in three
cases. In the domperidone group, one patient died before
tube insertion. In the control group, five patients were
excluded: the condition deteriorated rapidly in one patient
and he died before insertion; in the other four patients,
consent was withdrawn before insertion. Therefore, 298
patients were randomized and underwent tube insertion.
Of the 100 patients in the metoclopramide group, 95
patients received 20 mg metoclopramide according to the
protocol and five patients with renal insufficiency received
10 mg metoclopramide. In the domperidone group, 93
patients completed the trial in adherence to the protocol,
while the remaining six patients received 40 mg domperi-
done because they were transferred out of the ICU within
24 hours after tube insertion. There was no withdrawalFigure 1 Study profile.after tube insertion. All patients completed the 24-hour
observation and were included in the statistical analyses
(Figure 1).
Baseline data
Most demographic and primary diagnosis characteristics
were similar between the three groups (Table 1). Mean
age was over 60 years in each group. Respiratory and
neurologic diseases were the most common primary
diagnoses. Most patients received mechanical ventilation.
There was no difference in the frequency of use of seda-
tives, analgesics, vasopressors and mechanical ventilation.
The APACHE II score of each group was >20. APACHE II
and SOFA scores were similar between the three groups
(P >0.05).
The average time for tube insertion in all patients was
10.3 minutes, with 10.1 minutes in the metoclopramide
group, 9.6 minutes in the domperidone group and 11.0
minutes in the control group (P >0.05). The spiral
nasojejunal tube was successfully inserted into the
stomach in 92.2% of all patients after one to three attempts.
Only one patient underwent eight attempts before success-
ful placement because of a highly sensitive gag reflex. There
was no difference in attempts at tube insertion between the
three groups.
Table 1 Patients’ baseline characteristics
Variable Metoclopramide group Domperidone group Control group P value
(n = 100) (n = 99) (n = 99)
Age (years)
Average 62.1 ± 18.6 65.2 ± 15.1 61.3 ± 17.4 0.233
Median 64 69 64
Range 18 to 93 27 to 95 20 to 96
Male 67 (67.0) 58 (58.6) 72 (72.7) 0.107
Primary diagnosis
Respiratory 20 (20.0) 18 (18.2) 22 (22.2) 0.777
Cardiovascular 5 (5.0) 10 (10.1) 9 (9.1) 0.375
Neurological 48 (48.0) 41 (41.4) 39 (39.4) 0.439
Sepsis 14 (14.0) 11 (11.1) 13 (13.1) 0.822
Multitrauma 7 (7.0) 6 (6.1) 10 (10.1) 0.537
Other 6 (6.0) 13 (13.1) 6 (6.1) 0.114
Use of sedatives 31 (31.0) 30 (30.3) 29 (29.3) 0.966
Use of analgesics 10 (10.0) 12 (12.1) 9 (9.1) 0.773
Use of vasopressors 24 (24.0) 21 (21.2) 25 (25.3) 0.790
Ventilation 72 (72.0) 66 (66.7) 68 (68.7) 0.713
Average APACHE II score 21.7 ± 7.5 20.7 ± 6.6 21.0 ± 7.3 0.582
< 20 45 (45.0) 43 (43.4) 43 (43.4) 0.967
≥ 20 55 (55.0) 56 (56.6) 56 (56.6)
Average SOFA score 9.9 ± 2.9 9.7 ± 2.8 9.7 ± 2.9 0.858
< 12 66 (66.0) 68 (68.7) 66 (66.7) 0.916
≥ 12 34 (34.0) 31 (31.3) 33 (33.3)
Data presented as mean ± standard deviation, interquartile range or n (%). APACHE, Acute Physiology and Chronic Health Evaluation; SOFA, Sequential Organ
Failure Assessment.
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Twenty-four hours after tube insertion, successful post-
pyloric placement was achieved in 55 of 100 patients in
the metoclopramide group (55.0%), in 51 of 99 patients
in the domperidone group (51.5%) and in 27 of 99
patients in the control group (27.3%) (P = 0.0001). The
relative probability of success in the metoclopramide
group was 3.3 compared with the control group (95%
confidence interval (CI): 1.8 to 5.9, P = 0.0001). The relative
probability of success in the domperidone group was 2.8
compared with the control group (95% CI: 1.6 to 5.1,
P = 0.0005). There was no difference between the meto-
clopramide and the domperidone groups.
Secondary outcomes
The tubes migrated into D1 in eight patients, D2 in 13
patients, D3 in seven patients, D4 in eight patients and
proximal jejunum in 19 patients in the metoclopramide
group. The proportion of patients with post-D1, post-D2
and post-D3 placement in the metoclopramide group was
higher than in the control group. There was no difference
in the proportion of patients with tubes migrated intoproximal jejunum between the metoclopramide group
and the control group (odds ratio (OR) = 2.1; 95% CI: 0.9
to 4.8; P = 0.0752). In the domperidone group, the tubes
migrated into D1 in seven patients, D2 in four patients,
D3 in 14 patients, D4 in 10 patients and proximal jejunum
in 16 patients. The proportion of patients with post-D1,
post-D2 and post-D3 placement in the domperidone
group was higher than in the control group. There
was no difference in the proportion of patients with
tubes migrated into proximal jejunum between the
domperidone and control groups (OR = 1.7; 95% CI: 0.7
to 4.0; P = 0.2068) (Table 2).
There was no significant difference in the initial nose
scale of the tubes between the three groups. Twenty-four
hours after tube insertion, the average tube migration
distance was 10.8 cm (95% CI: 9.2 to 12.4) in the
metoclopramide group, 9.8 cm (95% CI: 8.1 to 11.5)
in the domperidone group and 5.5 cm (95% CI: 4.0
to 7.0) in the control group (P = 0.0001) (Table 2).
There was a 5.3 cm (95% CI: 1.9 to 8.7) longer average
migration distance in the metoclopramide group
compared with the control group (P <0.01), and a 4.3 cm
Table 2 Primary and secondary outcomes
Metoclopramide group Domperidone group Control group P value
(n = 100) (n = 99) (n = 99)
Tube tip position
Post-pyloric 55 (55.0)** 51 (51.5)** 27 (27.3) 0.0001
Post-D1 47 (47.0)** 44 (44.4)** 24 (24.2) 0.0015
Post-D2 34 (34.0)** 40 (40.4)** 13 (13.1) 0.0001
Post-D3 27 (27.0)* 26 (26.3)* 11 (11.1) 0.0088
Proximal jejunum 19 (19.0) 16 (16.2) 10 (10.1) 0.2016
Tube migration distance
Initial nose scale (cm) 75.3 ± 7.5 75.1 ± 7.0 75.2 ± 7.1 0.9708
Nose scale at 24 hours (cm) 86.1 ± 10.3† 84.9 ± 10.3† 80.6 ± 8.9 0.0003
Migration distance (cm) 10.8 ± 8.1† 9.8 ± 8.5† 5.5 ± 7.6 0.0001
Data presented as mean ± standard deviation or n (%). Post-pyloric, reaching the first portion of the duodenum or beyond. Post-D1, reaching the second portion
of the duodenum or beyond. Post-D2, reaching the third portion of the duodenum or beyond. Post-D3, reaching the fourth portion of the duodenum or beyond.
*P <0.016, metoclopramide group versus controls or domperidone group versus controls. **P <0.003, metoclopramide group versus controls or domperidone
group versus controls. †P <0.01, metoclopramide group versus controls or domperidone group versus controls.
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group compared with the control group (P <0.01). No
significant difference was observed in the migration dis-
tance between the metoclopramide and the domperidone
groups.
Safety
Safety of the study drugs and the tubes were assessed in
all patients according to all adverse events recorded
within 24 hours after tube insertion. There was no
difference in the incidence of any adverse events between
the three groups (Table 3). The most common drug-
related adverse events were lethargy, irritability, muscle
tremor and itching. These symptoms disappeared within
24 hours without any treatment. The overall incidence
was 1.7%, and there was no difference between the threeTable 3 Adverse events
Event Metoclopramide group
(n = 100)







Nasal mucosa bleeding 8 (8.0)




Data presented as n (%).groups. Nasal mucosa bleeding was the most common
tube-related event and was recorded in 21 patients (7.0%).
Bleeding stopped spontaneously without any treatment,
and there was no difference between the three groups
(P >0.05). The nasojejunal tube was misplaced into
airways in only one patient in the metoclopramide
group and one in the control group. The tube was pulled
out immediately and did not cause any adverse effect.
Other tube-related adverse events included pain, nausea
and vomiting, with an overall incidence of 6.0%. There
was no difference between the three groups (P >0.05).
Subgroup analyses
Success rates among prespecified subgroups of patients are
presented in Table 4. Prespecified analyses of the primary
endpoint, where patients were stratified according toDomperidone group Control group P value
(n = 99) (n = 99)




1 (1.0) 0 0.365
5 (5.1) 8 (8.1) 0.637
0 1 (1.0) 0.606
3 (3.0) 2 (2.0) 0.861
1 (1.0) 1 (1.0) 0.222
1 (1.0) 1 (1.0) 1.000
Table 4 Analysis of success rate of post-pyloric placement of the nasojejunal tube in prespecified subgroups
Subgroup Metoclopramide
group (n = 100)
Domperidone







<60 years 22/38 (57.9)* 19/35 (54.3)* 11/41 (26.8) 52/114 (45.6) 0.0100
≥60 years 33/62 (53.2)* 32/64 (50.0)* 16/58 (27.6) 81/184 (44.0) 0.0090
Sex
Male 38/67 (56.7)** 28/58 (48.3)* 17/72 (23.6) 83/197 (42.1) 0.0002
Female 17/33 (51.5) 23/41 (56.1) 10/27 (37.0) 50/101 (49.5) 0.2944
APACHE II score
< 20 31/45 (68.9)** 27/43 (62.8)* 14/43 (32.6) 72/131 (55.0)# 0.0013
≥ 20 24/55 (43.6) 24/56 (42.9) 13/56 (23.8) 61/167 (36.5) 0.0398
SOFA score
< 12 39/66 (59.1)* 37/68 (54.4)‡ 24/66 (36.4) 100/200 (50.0)† 0.0221
≥ 12 16/34 (47.1)** 14/31 (45.2)** 3/33 (9.1) 33/98 (33.7) 0.0012
Neurological diseases
Yes 27/48 (56.3)** 19/41 (46.3)∫ 9/39 (23.1) 55/128 (43.0) 0.0069
No 28/52 (53.8)* 32/58 (55.2)* 18/60 (30.0) 78/170 (45.9) 0.0089
Sepsis
Yes 9/14 (64.3)* 7/11 (63.6)* 2/13 (15.4) 18/38 (47.4) 0.0173
No 46/86 (53.5)** 44/88 (50.0)* 25/86 (29.1) 115/260 (44.2) 0.0023
Use of sedatives or analgesics
Yes 15/35 (42.9) 16/37 (43.2) 12/38 (31.6) 43/110 (39.1) 0.5023
No 40/65 (61.5)** 35/62 (56.5)** 15/61 (24.6) 90/188 (47.9) 0.0001
Use of vasopressors
Yes 10/24 (41.7) 8/21 (38.1) 4/25 (16.0) 22/70 (31.4)¶ 0.1129
No 45/76 (59.2)** 43/78 (55.1)** 23/74 (31.1) 111/228 (48.7) 0.0009
Mechanical ventilation
Yes 33/72 (45.8) 31/66 (47.0) 19/68 (27.9) 83/206 (40.3)‖ 0.0397
No 22/28 (78.6)** 20/33 (60.6)* 8/31 (25.8) 50/92 (54.3) 0.0002
Data presented as success/total (%). APACHE, Acute Physiology and Chronic Health Evaluation; SOFA, Sequential Organ Failure Assessment. *P <0.016,
metoclopramide or domperidone group versus controls. **P <0.0033, metoclopramide or domperidone group versus controls. #P = 0.0015, APACHE II score <20
versus ≥20. ‡P = 0.0360, SOFA <12 in the domperidone group versus controls. †P = 0.0077, SOFA score <12 versus ≥12. ∫P = 0.0292, neurologic diseases in the
domperidone group versus controls. ¶P = 0.0111, use of vasopressors versus without vasopressor. ‖P = 0.0241, mechanical ventilation versus no ventilation.
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gender and age, showed that both metoclopramide and
domperidone tended to improve the success rate of post-
pyloric placement. In patients with APACHE II score <20
(P <0.016), SOFA score ≥12 (P <0.0033), age ≥60 or <60
(both P <0.016), non-neurological disease (P <0.016), sep-
sis or not (P <0.016), without sedative and analgesic
(P <0.0033), without vasopressor (P <0.0033), without mech-
anical ventilation (P <0.016) and male patients (P <0.016),
both metoclopramide and domperidone improved the
success rate of post-pyloric placement compared with
controls. In patients with SOFA score <12 (P = 0.036) and
neurological disease (P = 0.0292), the proportion of post-
pyloric placement was higher in the metoclopramide
group compared with the domperidone group (Table 4).Independent factors influencing insertion success
All patients were divided into two groups according to
tube tip position. Patients with tubes in the stomach
were assigned to the failure group, and patients with
successful post-pyloric tube placement were assigned to
the success group. Influencing factors of tube migration
were analyzed. The proportion of patients with use of
prokinetic agents, APACHE II score <20, SOFA score <12,
without vasopressor and without mechanical ventilation
in the success group was significantly higher than in the
failure group (Table 5). APACHE II and SOFA scores were
included in a logistic regression analysis because they were
both used to access the severity of the illness. Logistic
multiple stepwise regression showed that use of prokinetic
agents, APACHE II score <20, SOFA score <12 and without







(n = 133) (n = 165)
Age <60 years 52 (39.1) 62 (37.6) 0.7881
Male 83 (62.4) 114 (69.1) 0.2255
Use of prokinetic agents 106 (79.7) 93 (56.4) 0.0001
APACHE II score <20 72 (54.1) 59 (35.8) 0.0015
SOFA score <12 100 (75.2) 100 (60.6) 0.0077
Non-neurological disease 78 (58.6) 92 (55.8) 0.6165
Non-sepsis 115 (86.5) 145 (87.9) 0.7163
Without sedative and analgesic 90 (67.7) 98 (59.4) 0.1411
Without vasopressor 111 (83.5) 117 (70.9) 0.0111
Without mechanical ventilation 50 (37.6) 42 (25.5) 0.0241
Data presented as n (%). APACHE, Acute Physiology and Chronic Health
Evaluation; SOFA, Sequential Organ Failure Assessment.
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success rate of post-pyloric placement (Table 6).
Discussion
This multicenter, randomized, open-label, controlled clin-
ical trial showed that both metoclopramide and domperi-
done can improve the success rate of post-pyloric
placement of spiral nasojejunal tubes in critically ill
patients. The success rate in the metoclopramide group
(55.0%) and the domperidone group (51.5%) was signifi-
cantly higher than that in the control group (27.3%). In
addition, there was a longer migration distance of the tubes
in the metoclopramide and domperidone groups than in
the control group. Logistic regression analysis identified use
of prokinetic agents, APACHE II score <20, SOFA score
<12 and without vasopressor as independent factors influ-
encing the success rate of the feeding tube migration. No
serious drug-related adverse reaction was observed.
Metoclopramide and domperidone are commonly used
as prokinetic agents in the ICU. Studies have shown thatTable 6 Multivariate logistic regression analysis of factors
for the success of post-pyloric placement
Influencing factor P value Odds ratio 95% CI
Including APACHE II score
Use of prokinetic agents <0.0001 3.155 1.843-5.401
APACHE II score <20 0.0030 2.098 1.286-3.421
Without vasopressor 0.0323 1.913 1.056-3.465
Including SOFA score
Use of prokinetic agents <0.0001 3.116 1.828-5.311
SOFA score <12 0.0223 1.853 1.092-3.146
Without vasopressor 0.0435 1.850 1.018-3.360
Data presented as n (%). APACHE, Acute Physiology and Chronic Health
Evaluation; CI, confidence interval; SOFA, Sequential Organ Failure Assessment.metoclopramide may improve gastrointestinal peristalsis,
increase gastric emptying and increase patients’ tolerance
to enteral nutrition [27-29], but did not reduce the
incidence of ventilation-associated pneumonia [30,31].
Metoclopramide was often used to promote the success
rate of bedside blind placement of nasojejunal tubes [32,33],
but its effects are controversial. An early prospective con-
trolled study showed that intravenous 10 mg metoclopra-
mide administered 10 minutes prior to intubation with a
small-bore feeding tube was ineffective in facilitating trans-
pyloric intubation [23]. Another study demonstrated that
metoclopramide administered after nasogastric intubation
was ineffective in promoting transpyloric advancement of
feeding tubes, but that there was a significant increase
in transpyloric intubation when metoclopramide was
administered prior to tube insertion [33]. A small clinical
trial by Lai and colleagues showed that 10 mg metoclopra-
mide administered prior to intubation achieved a success
rate of 57% in patients with gastric motility disorders [18].
A review including four studies demonstrated that there
was no statistically significant difference between intra-
venous or intramuscular metoclopramide administered to
promote tube migration (OR = 0.65, 95% CI: 0.33 to 1.28),
and that intravenous 10 mg metoclopramide (OR = 0.68,
95% CI: 0.37 to 1.23) and 20 mg metoclopramide
(OR = 0.27, 95% CI: 0.01 to 10.84) were equally ineffective
in facilitating transpyloric intubation [34]. The present
large trial showed that the success rate of post-pyloric
placement of nasojejunal tube increased significantly with
administration of metoclopramide. This is evidence sup-
porting the use of metoclopramide in spiral nasojejunal
tube insertion.
A number of clinical trials showed that domperidone
significantly improves patients’ gastrointestinal motility,
especially in diabetic patients with gastric paralysis.
Although domperidone is approved by the Chinese
Drugs Agency, it is not approved by the US Food and
Drug Administration to be used widely because of its
potential cardiac toxicity. A systemic evaluation by Sugumar
and colleagues suggested that domperidone may improve
the symptoms of diabetic patients with gastric paralysis by
improving gastric emptying [35]. However, there has been
no relevant study evaluating whether domperidone
can improve gastrointestinal motility and its effects
on the success rate of nasojejunal tube placement in
critically ill patients. In the present trial, the success
rate of post-pyloric placement of a spiral nasojejunal
tube in the domperidone group was 51.5%, similar to
that in the metoclopramide group (55.0%) and significantly
higher than in the control group (27.3%). Moreover, the
proportion of post-D1, post-D2 and post-D3 placement
was also higher than in the control group. The tubes
migrated for longer distances than in the control group in
both the metoclopramide and domperidone groups. These
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date as a prokinetic agent for post-pyloric placement of a
spiral nasojejunal tube in critical illness.
In the present study, there was also no difference in the
success rate of post-D1, post-D2, post-D3 and proximal
jejunum placement between the metoclopramide group
and the domperidone group. These results indicate that
the effect of domperidone may be similar to metoclopra-
mide in improving the success rate of spiral nasojejunal
tube insertion. However, the sample size of this study was
not enough to detect possible differences between the two
agents in improving post-pyloric migration placement. A
non-inferiority trial would be needed.
Erythromycin is another prokinetic agent commonly
used in the clinical setting and is often used to promote
the migration of spiral nasojejunal tubes. Early studies
suggested that erythromycin was effective in facilitating
the bedside placement of nasoenteric feeding tubes into
the duodenum in ICU patients [36,37]. However, some
studies observed different results. A randomized, double-
blind, placebo-controlled study in critical pediatric patients
by Gharpure and colleagues showed that erythromycin did
not facilitate the transpyloric passage of feeding tubes in
critically ill children. In addition, the distal migration of
duodenal tubes further into the small bowel was not
enhanced by erythromycin [38]. A randomized, controlled
trial including 40 subjects failed to determine any benefit of
erythromycin in terms of success or time of migration to
jejunal position using a self-propelled feeding tube [26].
Another randomized study showed that erythromycin was
more effective than metoclopramide in treating feed
intolerance, but that there was a rapid decline in both
treatments with time [39]. The reasons for these differences
may include patients’ heterogeneity, different tubes used
and tolerance to drugs [26], and also the fact that we
observed only the short-term efficacy for tube placement.
In addition, clinicians have to consider whether low-dose
erythromycin could induce bacterial drug resistance.
Erythromycin was therefore not selected as a prokinetic
agent in the present trial.
A retrospective analysis of 428 patients performed by
Metheny and colleagues found that a feeding tube in the
mid-duodenum and beyond could reduce the risk of
aspiration and associated pneumonia [40]. In the present
trial, the proportion of feeding tubes in the post-D1,
post-D2 and post-D3 position was 47.0%, 34.0% and
27.0%, respectively, in the metoclopramide group, all
significantly higher than in the control group. The
proportion of feeding tubes in the post-D1, post-D2 and
post-D3 position was 44.4%, 40.4% and 26.3%, respectively,
in the domperidone group, all significantly higher than in
the control group. These results indicated that the use of
either metoclopramide or domperidone for assistance of
spiral nasojejunal tube insertion may reduce the riskof aspiration and the incidence of hospital-acquired
pneumonia. It must be noted that the low proportion
of nasojejunal tube migration into the jejunum in the
present trial could indicate that spiral nasojejunal
tubes may not be the preferred route for patients
with diseases requiring strict jejunum feeding, such as
acute pancreatitis.
Karsenti and colleagues found that the ligament of
Treitz was reached in a median of 12 hours (range 1 to
96 hours) when the nasoenteric Flocare tube was used
for severe acute pancreatitis [41]. Berger and colleagues
found that the success rate of post-pyloric placement
was 40% at 24 hours after insertion, while a success rate
of 58% was achieved at 72 hours [17]. However, a study
by van den Bosch and colleagues indicated that the
nasojejunal tube did not migrate beyond the pylorus
although the observation time was extended to 48 hours
in patients with first failed insertion [26]. In addition,
nutrition support guidelines by the Society of Critical
Care Medicine and the American Society for Parenteral
and Enteral Nutrition in critically ill adult patients with
intolerance to gastric feeding suggest that enteral nutrition
should be initiated within 24 to 48 hours after admission
to the ICU, and that the nutrition goal should be achieved
within 48 to 72 hours [42]. Therefore, in the present trial,
tube tip positions were confirmed by abdominal X-ray
scan 24 hours after insertion in all patients.
Complications associated with nasojejunal tubes include
inadvertent misplacement of the tube, epistaxis, sinusitis,
inadvertent tube removal, tube clogging, tube-feeding-
associated diarrhea and aspiration pneumonia [43]. The
incidence of airway misplacement of feeding tubes at a
major tertiary referral university hospital was 3.2% [44].
Duodenal perforation due to a kink in a nasojejunal feeding
tube in a patient with severe acute pancreatitis was also
reported [45]. Nasal mucosa bleeding was the most
common adverse event associated with tube insertion,
with an incidence of 7.0%, in the present study. The
bleeding stopped spontaneously without any treatment.
The tubes were misplaced into airways in two patients
and removed immediately. No serious adverse effect on
the patients was observed due to the misplacement. A
slight muscle tremor was observed in only one patient
after administration of metoclopramide. The symptom
disappeared without any treatment. No cardiac adverse
effect was observed in all patients who received domperi-
done. The low incidence (1.7%) of suspected drug-related
adverse events, without significant difference from the
control group, indicated that metoclopramide and
domperidone were safe using the doses used in the
present study. However, subjective sensations such as
headache, severe thirst, and pronunciation difficulties were
difficult to assess due to the severity of disease, sedation or
analgesia and mechanical ventilation.
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the success rate of post-pyloric placement of spiral
nasojejunal tubes were analyzed in all subgroups
including age, sex, APACHE II score, SOFA score,
diagnosis of neurologic diseases and sepsis, and use of
sedatives, analgesics and vasopressors. The aim of analyzing
different prespecified subgroups was in preparation for a
future study targeting specific groups of critically ill
patients who might benefit from prokinetic agents, because
it is unlikely that prokinetic agents are equally beneficial to
all patients in view of the significant heterogeneity in
patients’ characteristics, severity of illness and treatments in
critically ill patients. Analysis of the current study showed
that patients with APACHE II score <20, SOFA score ≥12,
age ≥60 or <60, non-neurological disease, sepsis or not,
without mechanical ventilation, without sedative and
analgesic, without vasopressor and male patients benefited
from the use of prokinetic agents, which provides
evidence for tailored therapy. The results of subgroup
analyses in the present study were inconclusive and whether
prokinetic agents are more effective in specific groups of
patients with spiral nasojejunal tube placement in the ICU
should be explored in trials with larger sample sizes.
All patients were divided according to success or failure
of tube tip migration beyond the pylorus. Logistic regres-
sion analysis found that use of prokinetic agents, APACHE
II score <20, SOFA score <12 and without vasopressor were
independent factors influencing the success rate of tube
insertion, which was consistent with a study by Berger and
colleagues [17]. The success rate of post-pyloric placement
of a spiral nasojejunal tube may be relatively high in
patients with the above factors. The higher success of this
study in patients with lower disease severity may suggest
that this drug/tube technique may be less successful in
those with greatest need for intestinal feeding. Therefore,
spiral nasojejunal tubes may be the preferred and most
reliable route for enteral nutrition in such patients.
A recent study has suggested that electromagnetic
guiding of the tube resulted in a high placement success rate
(97.2% vs. 27 to 55% in the present study) [46]. This could
replace the X-ray confirmation of tube placement since
about 10.5% of the radiologic interpretations can be inaccur-
ate [47]. The use of the electromagnetic guiding resulted in
success rates that were comparable with endoscopic place-
ment [48]. Further studies will be required to compare these
technologies with the use of prokinetic agents. However,
limited access to new technologies might be an impediment
to their implementation in some countries.
To the best of our knowledge, this is the first multi-
center, randomized, controlled trial to confirm whether
prokinetic agents can promote the success rate of post-
pyloric placement of self-propelling spiral nasojejunal feed-
ing tubes. To minimize the potential bias, randomization
was conducted in the study, but fixed block randomizationwas used, which could introduce a bias if the block size is
guessed. Meanwhile, the radiograph of each patient was
assessed by an expert group of ICU clinicians and radiolo-
gists who were independent and blinded to the treatment
allocation, thus reducing the bias to a great extent and
increasing the validity of the results. The reason for the
lower success rate of post-pyloric placement of nasojejunal
tubes compared with some previous studies may be
explained by the severity of patients enrolled in this trial. In
the present study, the absence of double-blinding limits the
extent to which the results can be generalized. Double-
blinding could not be used because of the absence of a
placebo with an identical appearance to domperidone
suspension, and because of the different dosing regimen of
the two drugs. Only the patients and the statistician were
blinded. In addition, we only examined one type of tube
(Flocare Bengmark; Nutricia), while a previous study
showed that other types of tubes (such as the Tiger tube;
Cook, Bjaeverskov, Denmark) might result in a higher effi-
cacy [49]. Moreover, all patients who underwent major
surgery were excluded, limiting the number of patients
despite the large number of participating hospitals. Finally,
we included all patients, irrespective of their gastric
emptying status. Further studies should be conducted in
patients stratified based on gastric emptying.Conclusions
The present trial strongly suggests that either metoclopra-
mide or domperidone may facilitate post-pyloric placement
of spiral nasojejunal tubes in critically ill patients. Either
metoclopramide or domperidone may facilitate post-D1,
post-D2 and post-D3 placement of spiral nasojejunal tubes.
No serious adverse event was observed with administration
of metoclopramide or domperidone. Use of prokinetic
agents, APACHE II score <20, SOFA score <12 and with-
out vasopressor were independent factors influencing the
success rate of tube insertion.Key messages
 Either metoclopramide or domperidone may
facilitate post-pyloric placement of spiral nasojejunal
tubes in critically ill patients.
 Either metoclopramide or domperidone may
facilitate post-D1, post-D2 and post-D3 placement of
spiral nasojejunal tubes.
 No serious adverse event was observed with
administration of metoclopramide or domperidone.
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